Epidermal growth factor receptor 2 (HER2) amplification occurs in many types of cancer, including breast, gastric, colon, bladder, and biliary cancers, but anti-HER2 therapy in HGSOC has not yet been fully evaluated [6]. Here, ERBB2 is linked to cancer.